Italy · Delayed Price · Currency is EUR Pharmanutra Statistics
Total Valuation
Pharmanutra has a market cap or net worth of EUR 856.02 million. The enterprise value is 846.12 million.
| Market Cap | 856.02M |
| Enterprise Value | 846.12M |
Important Dates
The next estimated earnings date is Tuesday, September 8, 2026.
| Earnings Date | Sep 8, 2026 |
| Ex-Dividend Date | May 4, 2026 |
Share Statistics
Pharmanutra has 9.58 million shares outstanding. The number of shares has decreased by -0.54% in one year.
| Current Share Class | 9.58M |
| Shares Outstanding | 9.58M |
| Shares Change (YoY) | -0.54% |
| Shares Change (QoQ) | +0.37% |
| Owned by Insiders (%) | 65.81% |
| Owned by Institutions (%) | 11.17% |
| Float | 3.27M |
Valuation Ratios
The trailing PE ratio is 40.62 and the forward PE ratio is 34.69.
| PE Ratio | 40.62 |
| Forward PE | 34.69 |
| PS Ratio | 6.16 |
| PB Ratio | 11.49 |
| P/TBV Ratio | 17.18 |
| P/FCF Ratio | 53.45 |
| P/OCF Ratio | 44.01 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 25.10, with an EV/FCF ratio of 52.83.
| EV / Earnings | 40.25 |
| EV / Sales | 6.09 |
| EV / EBITDA | 25.10 |
| EV / EBIT | 27.74 |
| EV / FCF | 52.83 |
Financial Position
The company has a current ratio of 2.38, with a Debt / Equity ratio of 0.26.
| Current Ratio | 2.38 |
| Quick Ratio | 1.84 |
| Debt / Equity | 0.26 |
| Debt / EBITDA | 0.57 |
| Debt / FCF | 1.19 |
| Interest Coverage | 50.50 |
Financial Efficiency
Return on equity (ROE) is 30.15% and return on invested capital (ROIC) is 32.37%.
| Return on Equity (ROE) | 30.15% |
| Return on Assets (ROA) | 15.16% |
| Return on Invested Capital (ROIC) | 32.37% |
| Return on Capital Employed (ROCE) | 31.53% |
| Weighted Average Cost of Capital (WACC) | 4.92% |
| Revenue Per Employee | 992,429 |
| Profits Per Employee | 150,157 |
| Employee Count | 128 |
| Asset Turnover | 1.11 |
| Inventory Turnover | 8.08 |
Taxes
In the past 12 months, Pharmanutra has paid 10.45 million in taxes.
| Income Tax | 10.45M |
| Effective Tax Rate | 33.30% |
Stock Price Statistics
The stock price has increased by +87.82% in the last 52 weeks. The beta is 0.13, so Pharmanutra's price volatility has been lower than the market average.
| Beta (5Y) | 0.13 |
| 52-Week Price Change | +87.82% |
| 50-Day Moving Average | 84.73 |
| 200-Day Moving Average | 63.36 |
| Relative Strength Index (RSI) | 53.22 |
| Average Volume (20 Days) | 13,003 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Pharmanutra had revenue of EUR 138.94 million and earned 21.02 million in profits. Earnings per share was 2.20.
| Revenue | 138.94M |
| Gross Profit | 70.63M |
| Operating Income | 30.50M |
| Pretax Income | 31.40M |
| Net Income | 21.02M |
| EBITDA | 33.23M |
| EBIT | 30.50M |
| Earnings Per Share (EPS) | 2.20 |
Balance Sheet
The company has 29.00 million in cash and 19.10 million in debt, with a net cash position of 9.91 million or 1.03 per share.
| Cash & Cash Equivalents | 29.00M |
| Total Debt | 19.10M |
| Net Cash | 9.91M |
| Net Cash Per Share | 1.03 |
| Equity (Book Value) | 74.47M |
| Book Value Per Share | 7.76 |
| Working Capital | 43.28M |
Cash Flow
In the last 12 months, operating cash flow was 19.45 million and capital expenditures -3.43 million, giving a free cash flow of 16.02 million.
| Operating Cash Flow | 19.45M |
| Capital Expenditures | -3.43M |
| Depreciation & Amortization | 2.73M |
| Net Borrowing | -4.96M |
| Free Cash Flow | 16.02M |
| FCF Per Share | 1.67 |
Margins
Gross margin is 50.83%, with operating and profit margins of 21.95% and 15.13%.
| Gross Margin | 50.83% |
| Operating Margin | 21.95% |
| Pretax Margin | 22.60% |
| Profit Margin | 15.13% |
| EBITDA Margin | 23.92% |
| EBIT Margin | 21.95% |
| FCF Margin | 11.53% |
Dividends & Yields
This stock pays an annual dividend of 1.20, which amounts to a dividend yield of 1.33%.
| Dividend Per Share | 1.20 |
| Dividend Yield | 1.33% |
| Dividend Growth (YoY) | 20.00% |
| Years of Dividend Growth | 5 |
| Payout Ratio | 45.62% |
| Buyback Yield | 0.54% |
| Shareholder Yield | 1.85% |
| Earnings Yield | 2.46% |
| FCF Yield | 1.87% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for Pharmanutra is 94.33, which is 5.52% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 94.33 |
| Price Target Difference | 5.52% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | 15.63% |
| EPS Growth Forecast (3Y) | 20.66% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Pharmanutra has an Altman Z-Score of 7.99 and a Piotroski F-Score of 6.
| Altman Z-Score | 7.99 |
| Piotroski F-Score | 6 |